[
  {
    "ts": null,
    "headline": "1 Growth Stock Under $100 to Buy Before It Soars",
    "summary": "This biotech under $100 looks like a growth opportunity worth grabbing before it soars.",
    "url": "https://finnhub.io/api/news?id=01be0cce44661729083567b934db9292a886263e483b3e7a501b101515325514",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761676921,
      "headline": "1 Growth Stock Under $100 to Buy Before It Soars",
      "id": 137244505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "This biotech under $100 looks like a growth opportunity worth grabbing before it soars.",
      "url": "https://finnhub.io/api/news?id=01be0cce44661729083567b934db9292a886263e483b3e7a501b101515325514"
    }
  },
  {
    "ts": null,
    "headline": "Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio",
    "summary": "Discover why Incyte Corporation is a top Buy with robust Q3 2025 results, pipeline advances, and promising oncology data. Click for my updated look at INCY stock.",
    "url": "https://finnhub.io/api/news?id=9f1d96dc0592cd0b2fc07b77244657a7cbcf56f55c3f428e81ca5c9bedfa425d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761673898,
      "headline": "Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio",
      "id": 137240757,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238109475/image_2238109475.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Discover why Incyte Corporation is a top Buy with robust Q3 2025 results, pipeline advances, and promising oncology data. Click for my updated look at INCY stock.",
      "url": "https://finnhub.io/api/news?id=9f1d96dc0592cd0b2fc07b77244657a7cbcf56f55c3f428e81ca5c9bedfa425d"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Securities Maintains a Buy on Incyte Corporation (INCY)",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Fye […]",
    "url": "https://finnhub.io/api/news?id=cf2a029130e37f1deb27b9fc90df1976a7db5f01085febcfa00f66b16d4e9198",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761668647,
      "headline": "Bank of America Securities Maintains a Buy on Incyte Corporation (INCY)",
      "id": 137244507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Fye […]",
      "url": "https://finnhub.io/api/news?id=cf2a029130e37f1deb27b9fc90df1976a7db5f01085febcfa00f66b16d4e9198"
    }
  },
  {
    "ts": null,
    "headline": "Why Incyte (INCY) Stock Is Trading Lower Today",
    "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.",
    "url": "https://finnhub.io/api/news?id=66082906d236c657807995142698bf462e704054b335bde2be530be37991fcc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761667895,
      "headline": "Why Incyte (INCY) Stock Is Trading Lower Today",
      "id": 137244508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.",
      "url": "https://finnhub.io/api/news?id=66082906d236c657807995142698bf462e704054b335bde2be530be37991fcc0"
    }
  },
  {
    "ts": null,
    "headline": "INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales",
    "summary": "Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.",
    "url": "https://finnhub.io/api/news?id=6d7c29247e6a34a74766df166b4153ed545c89d78024275bb2fd5e843c170cd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761664140,
      "headline": "INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales",
      "id": 137243279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.",
      "url": "https://finnhub.io/api/news?id=6d7c29247e6a34a74766df166b4153ed545c89d78024275bb2fd5e843c170cd1"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Q3 2025 Earnings Call Transcript",
    "summary": "William Meury: Thank you, Alexis, and good morning, everyone.  In terms of the core business, my assessment has reinforced my confidence in the growth potential of our key products.  The fundamentals around Jakafi, Opzelura, and our hematology business, Naktinvo and Monjuvi, namely, remain strong.",
    "url": "https://finnhub.io/api/news?id=2755ff2eeaccb1bd442b57d755d27d942d7ae9e9b2e7dc3f8d96cdedfa5682ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761661759,
      "headline": "Incyte (INCY) Q3 2025 Earnings Call Transcript",
      "id": 137244510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "William Meury: Thank you, Alexis, and good morning, everyone.  In terms of the core business, my assessment has reinforced my confidence in the growth potential of our key products.  The fundamentals around Jakafi, Opzelura, and our hematology business, Naktinvo and Monjuvi, namely, remain strong.",
      "url": "https://finnhub.io/api/news?id=2755ff2eeaccb1bd442b57d755d27d942d7ae9e9b2e7dc3f8d96cdedfa5682ba"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views",
    "summary": "Incyte stock edged down Tuesday despite widely beating third-quarter forecasts, on its light 2025 outlook.",
    "url": "https://finnhub.io/api/news?id=944d036b17d558a19f042483d50eb7db751086c3f4fdcb39d48835ca9b743d19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761659184,
      "headline": "Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views",
      "id": 137238340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte stock edged down Tuesday despite widely beating third-quarter forecasts, on its light 2025 outlook.",
      "url": "https://finnhub.io/api/news?id=944d036b17d558a19f042483d50eb7db751086c3f4fdcb39d48835ca9b743d19"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say",
    "summary": "While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=02446f00b77b832c1f450cbc0a68fa6315ab15fd9631a35eb82c6e215afb9771",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761658203,
      "headline": "Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say",
      "id": 137238341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=02446f00b77b832c1f450cbc0a68fa6315ab15fd9631a35eb82c6e215afb9771"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Tops Q3 Earnings and Revenue Estimates",
    "summary": "Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=5102948b4844b5584529d0a43f6d545be6a1c387f1a7137e41b3713bb78853fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761653702,
      "headline": "Incyte (INCY) Tops Q3 Earnings and Revenue Estimates",
      "id": 137238342,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=5102948b4844b5584529d0a43f6d545be6a1c387f1a7137e41b3713bb78853fd"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript",
    "summary": "Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDTCompany ParticipantsAlexis SmithWilliam Meury - CEO, President &...",
    "url": "https://finnhub.io/api/news?id=64d3fa7ee37bd1d6158e2da9a5451a8d3c31995f52ee9f72cf057b662534dd3d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761651711,
      "headline": "Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript",
      "id": 137239630,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDTCompany ParticipantsAlexis SmithWilliam Meury - CEO, President &...",
      "url": "https://finnhub.io/api/news?id=64d3fa7ee37bd1d6158e2da9a5451a8d3c31995f52ee9f72cf057b662534dd3d"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (NASDAQ:INCY) Reports Strong Q3",
    "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=6a981dea0827afca0eef418e5528b5307608b746d6d1fe86353e13e1bec57fb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761650337,
      "headline": "Incyte (NASDAQ:INCY) Reports Strong Q3",
      "id": 137238343,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=6a981dea0827afca0eef418e5528b5307608b746d6d1fe86353e13e1bec57fb0"
    }
  },
  {
    "ts": null,
    "headline": "Incyte: Q3 Earnings Snapshot",
    "summary": "WILMINGTON, Del. AP) — Incyte Corp. INCY) on Tuesday reported third-quarter earnings of $424.2 million.",
    "url": "https://finnhub.io/api/news?id=39d224fbaabd5c2751b9cfa14b63917558b5a80ba9fafeca900146d3dce00407",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761649801,
      "headline": "Incyte: Q3 Earnings Snapshot",
      "id": 137238344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del. AP) — Incyte Corp. INCY) on Tuesday reported third-quarter earnings of $424.2 million.",
      "url": "https://finnhub.io/api/news?id=39d224fbaabd5c2751b9cfa14b63917558b5a80ba9fafeca900146d3dce00407"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates",
    "summary": "WILMINGTON, Del., October 28, 2025--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates",
    "url": "https://finnhub.io/api/news?id=c60f5e4752e93ca922d141a7205b56576be364beb414d32f080ec52acec3e860",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761649200,
      "headline": "Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates",
      "id": 137238345,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., October 28, 2025--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates",
      "url": "https://finnhub.io/api/news?id=c60f5e4752e93ca922d141a7205b56576be364beb414d32f080ec52acec3e860"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corporation 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-28. The following slide deck was published by Incyte Corporation in conjunction with their 2025 Q3 earnings call.",
    "url": "https://finnhub.io/api/news?id=f8df4e2ca3e27e2dd9f41054662a6bb1b12ee5a640e7d52882bb042aeb6fa5b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761640533,
      "headline": "Incyte Corporation 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137237195,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "2025-10-28. The following slide deck was published by Incyte Corporation in conjunction with their 2025 Q3 earnings call.",
      "url": "https://finnhub.io/api/news?id=f8df4e2ca3e27e2dd9f41054662a6bb1b12ee5a640e7d52882bb042aeb6fa5b2"
    }
  }
]